Insights on ADC Therapeutics Pipeline and Oncology Research

ADC Therapeutics focuses its oncology research on antibody drug conjugates, which are designed to deliver potent therapeutic payloads to cancer cells through targeted antibodies. Its leading medicine, ZYNLONTA, is a CD19 directed ADC used in certain B cell lymphomas. Current research is focused on expanding its potential applications and studying combinations with other treatments.

ADC Therapeutics Pipeline and Current Clinical Research

The company’s clinical development activities currently center heavily on ZYNLONTA, also known as loncastuximab tesirine. Research is examining its use in different treatment settings and combinations for patients with B cell non Hodgkin lymphoma. The LOTIS clinical program represents an important part of this research strategy.

Key areas of ongoing research include:

• LOTIS 5: A Phase 3 study evaluated ZYNLONTA combined with rituximab against R GemOx in relapsed or refractory diffuse large B cell lymphoma. The study achieved its primary progression free survival endpoint.
• LOTIS 7: This Phase 1b study is evaluating ZYNLONTA in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab in relapsed or refractory B cell non Hodgkin lymphoma.
• Additional lymphoma research: Investigator initiated studies are examining ZYNLONTA in follicular lymphoma and marginal zone lymphoma.
• Future targeted research: ADC Therapeutics has also reported completing IND enabling activities for an exatecan based ADC targeting prostate specific membrane antigen, while exploring partnership opportunities.

These programs demonstrate how ADC research can involve both established drug candidates and newer targeted approaches.

Oncology Research Directions and Future Development

ADC technology continues to be investigated as a way to combine the targeting capabilities of antibodies with potent therapeutic payloads. ZYNLONTA uses a CD19 directed antibody to identify CD19 expressing cells and delivers a PBD payload after internalization.

ADC Therapeutics is also studying whether combining ZYNLONTA with other therapies can provide additional treatment options. LOTIS 7 completed enrollment of 100 patients at the selected dose in June 2026, with full data expected later in 2026.

Important research considerations include:

• Combination therapy: Researchers are assessing ZYNLONTA alongside bispecific antibodies and other targeted medicines.
• Disease expansion: Studies are investigating whether the therapy may have applications beyond currently established lymphoma settings.
• Clinical evidence: Phase 2 and Phase 3 research helps researchers evaluate response rates, progression free survival, overall survival, and safety.
• Regulatory development: Positive clinical evidence may support future regulatory submissions and potential expansion of approved treatment uses.

Overall, ADC Therapeutics’ pipeline illustrates the continuing development of antibody drug conjugates within oncology research. Current work remains focused on generating clinical evidence for ZYNLONTA, investigating combination approaches, and exploring additional targeted ADC technologies. As clinical studies progress, future results will help determine which research programs may advance into broader development and regulatory evaluation.